175 related articles for article (PubMed ID: 17225121)
41. Transforming growth factor beta 1 and monocyte chemoattractant protein-1 as prognostic markers of diabetic nephropathy.
Shaker OG; Sadik NA
Hum Exp Toxicol; 2013 Oct; 32(10):1089-96. PubMed ID: 23515495
[TBL] [Abstract][Full Text] [Related]
42. Elevated serum levels of interleukin-18 in patients with overt diabetic nephropathy: effects of miglitol.
Uzu T; Yokoyama H; Itoh H; Koya D; Nakagawa A; Nishizawa M; Maegawa H; Yokomaku Y; Araki S; Abiko A; Haneda M
Clin Exp Nephrol; 2011 Feb; 15(1):58-63. PubMed ID: 20824296
[TBL] [Abstract][Full Text] [Related]
43. Factors associated with progression of diabetic nephropathy in Japanese elderly patients with type 2 diabetes: sub-analysis of the Japanese Elderly Diabetes Intervention Trial.
Araki S; Nishio Y; Araki A; Umegaki H; Sakurai T; Iimuro S; Ohashi Y; Uzu T; Maegawa H; Kashiwagi A; Ito H;
Geriatr Gerontol Int; 2012 Apr; 12 Suppl 1():127-33. PubMed ID: 22435948
[TBL] [Abstract][Full Text] [Related]
44. Polymorphisms of the protein kinase C-beta gene (PRKCB1) accelerate kidney disease in type 2 diabetes without overt proteinuria.
Araki S; Haneda M; Sugimoto T; Isono M; Isshiki K; Kashiwagi A; Koya D
Diabetes Care; 2006 Apr; 29(4):864-8. PubMed ID: 16567829
[TBL] [Abstract][Full Text] [Related]
45. Urinary heme oxygenase-1 as a potential biomarker for early diabetic nephropathy.
Li Z; Xu Y; Liu X; Nie Y; Zhao Z
Nephrology (Carlton); 2017 Jan; 22(1):58-64. PubMed ID: 26733347
[TBL] [Abstract][Full Text] [Related]
46. Cardiac autonomic neuropathy and early progressive renal decline in patients with nonmacroalbuminuric type 1 diabetes.
Orlov S; Cherney DZ; Pop-Busui R; Lovblom LE; Ficociello LH; Smiles AM; Warram JH; Krolewski AS; Perkins BA
Clin J Am Soc Nephrol; 2015 Jul; 10(7):1136-44. PubMed ID: 26092828
[TBL] [Abstract][Full Text] [Related]
47. The Expression of Tristetraprolin and Its Relationship with Urinary Proteins in Patients with Diabetic Nephropathy.
Liu F; Guo J; Zhang Q; Liu D; Wen L; Yang Y; Yang L; Liu Z
PLoS One; 2015; 10(10):e0141471. PubMed ID: 26517838
[TBL] [Abstract][Full Text] [Related]
48. Anemia is associated with an elevated serum level of high-molecular-weight adiponectin in patients with type 2 diabetes independently of renal dysfunction.
Aso Y; Suganuma R; Wakabayashi S; Hara K; Nakano T; Suetsugu M; Matsumoto S; Nakamachi T; Takebayashi K; Morita K; Inukai T
Transl Res; 2009 Oct; 154(4):175-82. PubMed ID: 19766961
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of serum cystatin C and chromogranin A as markers of nephropathy in patients with type 2 diabetes mellitus.
Mojiminiyi OA; Abdella N; George S
Scand J Clin Lab Invest; 2000 Oct; 60(6):483-9. PubMed ID: 11129064
[TBL] [Abstract][Full Text] [Related]
50. Serum and urinary type IV collagen concentrations in the assessment of diabetic microangiopathy.
Banu N; Hara H; Egusa G; Yamakido M
Hiroshima J Med Sci; 1994 Dec; 43(4):123-33. PubMed ID: 7883578
[TBL] [Abstract][Full Text] [Related]
51. Risk factors for progression of renal disease in patient with diabetic nephropathy.
Unsal A; Koc Y; Basturk T; Akgun AO; Sakaci T; Ahbap E
Eur Rev Med Pharmacol Sci; 2012 Jul; 16(7):878-83. PubMed ID: 22953635
[TBL] [Abstract][Full Text] [Related]
52. Elevated placental growth factor (PlGF) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.
Tarnow L; Astrup AS; Parving HH
Scand J Clin Lab Invest Suppl; 2005; 240():73-9. PubMed ID: 16112962
[TBL] [Abstract][Full Text] [Related]
53. Implication of decreased serum complement 3 in patients with diabetic nephropathy.
Zhang J; Wang Y; Zhang R; Li H; Han Q; Guo R; Wang T; Li L; Liu F
Acta Diabetol; 2018 Jan; 55(1):31-39. PubMed ID: 29043511
[TBL] [Abstract][Full Text] [Related]
54. Soluble serum Klotho in diabetic nephropathy: relationship to VEGF-A.
Kacso IM; Bondor CI; Kacso G
Clin Biochem; 2012 Nov; 45(16-17):1415-20. PubMed ID: 22836100
[TBL] [Abstract][Full Text] [Related]
55. Glomerular filtration rate changes in normoalbuminuric and microalbuminuric Type 2 diabetic patients and normal individuals A 10-year follow-up.
Murussi M; Gross JL; Silveiro SP
J Diabetes Complications; 2006; 20(4):210-5. PubMed ID: 16798471
[TBL] [Abstract][Full Text] [Related]
56. Epidermal growth factor receptor and podocin predict nephropathy progression in type 2 diabetic patients through interaction with the autophagy influencer ULK-1.
El-Shazly AAA; Sallam AM; El-Hefnawy MH; El-Mesallamy HO
J Diabetes Complications; 2019 Feb; 33(2):128-133. PubMed ID: 30545560
[TBL] [Abstract][Full Text] [Related]
57. Serum fibrinogen predicts diabetic ESRD in patients with type 2 diabetes mellitus.
Zhang J; Wang Y; Zhang R; Li H; Han Q; Wu Y; Wang S; Guo R; Wang T; Li L; Liu F
Diabetes Res Clin Pract; 2018 Jul; 141():1-9. PubMed ID: 29684616
[TBL] [Abstract][Full Text] [Related]
58. Osteopontin is a strong predictor of incipient diabetic nephropathy, cardiovascular disease, and all-cause mortality in patients with type 1 diabetes.
Gordin D; Forsblom C; Panduru NM; Thomas MC; Bjerre M; Soro-Paavonen A; Tolonen N; Sandholm N; Flyvbjerg A; Harjutsalo V; Groop PH;
Diabetes Care; 2014 Sep; 37(9):2593-600. PubMed ID: 24969575
[TBL] [Abstract][Full Text] [Related]
59. Validation of a protein biomarker test for predicting renal decline in type 2 diabetes: The Fremantle Diabetes Study Phase II.
Peters KE; Davis WA; Ito J; Bringans SD; Lipscombe RJ; Davis TME
J Diabetes Complications; 2019 Dec; 33(12):107406. PubMed ID: 31669066
[TBL] [Abstract][Full Text] [Related]
60. Risk factors associated with the development of overt nephropathy in type 2 diabetes patients: a 12 years observational study.
Viswanathan V; Tilak P; Kumpatla S
Indian J Med Res; 2012 Jul; 136(1):46-53. PubMed ID: 22885263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
